The Integris Medtech IPO may open on 27 November and close on 1 December, as per an Economic Times report. The Gurugram-based medical devices company wants to raise ₹2,500–3,000 crore. The company has not confirmed the dates or the size.
What ET reports
ET cites people familiar with the matter. The company and its bankers did not reply to ET's emails before it published.
| Item | As reported |
|---|---|
| Opens | 27 November 2026 |
| Closes | 1 December 2026 |
| Issue size | ₹2,500–3,000 crore |
| Structure | Fresh issue plus offer for sale (OFS) |
| Lead managers | ICICI Securities, Axis Capital, Citigroup, IIFL Capital Services |
The OFS is the part where existing shareholders sell their shares. The price band, lot size and listing date are not out yet. They will come with the red herring prospectus (RHP), the final offer document.
Where will the money go?
The company plans to use 85% of the net proceeds from the fresh issue to repay debt. The loans sit in its wholly owned and step-down subsidiaries. So most of the new money goes to clearing debt.
Integris makes cardiovascular devices, clinical diagnostics products and laboratory solutions. It sells them in markets outside India as well.
What does the company do?
Integris Medtech is a global medical products and laboratory solutions company. It has three main businesses. These are cardiovascular devices, clinical diagnostics and scientific laboratory solutions.
It develops, makes and sells a wide range of medical devices and laboratory products. Its customers are in international markets, not only in India. The company is headquartered in Gurugram.
Why the debt repayment matters
Most of the fresh money will not build new factories. It will pay down loans held by subsidiaries. Lower debt can cut the interest the company pays each year, but it does not add new business by itself.
The RHP should list which subsidiary loans will be repaid and how much each gets. Read that section when it is out. The promoters and other sellers in the OFS get the money from their own shares, not the company.
What our data shows
The size looks very different from our last report. In October, the company cut its fresh issue to ₹600 crore from ₹925 crore, as we covered in our earlier post on the Integris Medtech IPO. If ET's size is right, the OFS would be the bigger part, at more than ₹1,900 crore. That is our arithmetic, not a reported figure.
What happens next
Watch for the RHP, which should carry the price band and the exact OFS size. Until then, treat the dates and size as a report. You can track every dated issue on our upcoming mainboard IPO page. The report is on The Economic Times.